槐杞黄颗粒联合CCLG-ALL2008方案对急性淋巴细胞白血病维持期患儿的临床研究

Clinical study of Huaiqihuang Granule Combined with CCLG-ALL2008 Regimen on Children with Maintenance Phase of Acute Lymphoblastic Leukemia

目的:探讨槐杞黄颗粒联合CCLG-ALL2008方案治疗急性淋巴细胞白血病(ALL)维持期患儿的临床疗效。方法:选择2017年5月~2019年3月期间我院收治的62例ALL维持期患儿,采用随机数字表法将患儿分为对照组(CCLG-ALL2008方案治疗,n=31)和研究组(槐杞黄颗粒联合CCLG-ALL2008方案治疗,n=31)。观察两组临床症状情况、血清炎症因子和免疫球蛋白水平、T淋巴细胞亚群的变化,同时记录两组不良反应发生率。结果:研究组平均白细胞水平高于对照组,感染发作次数少于对照组,抗生素使用时间短于对照组(P<0.05)。研究组治疗后CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于对照组,CD8^(+)低于对照组(P<0.05)。研究组治疗后免疫球蛋白A(Ig A)、免疫球蛋白G(Ig G)高于对照组(P<0.05)。对照组、研究组患儿治疗后免疫球蛋白M(Ig M)组内对比,无统计学差异(P>0.05)。研究组治疗后C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、降钙素原(PCT)、白细胞介素-6(IL-6)低于对照组(P<0.05)。两组不良反应总发生率对比,无显著性差异(P>0.05)。结论:槐杞黄颗粒联合CCLG-ALL2008方案治疗ALL维持期患儿,可减轻患儿炎症反应,提高其免疫功能,减少感染发作次数,缩短抗生素使用时间,安全有效。

Objective: To explore the clinical efficacy of Huaiqihuang granule combined with CCLG-ALL2008 regimen in the treatment of children with maintenance phase of acute lymphoblastic leukemia(ALL). Methods: 62 cases of children with maintenance phase of ALL who were treated in our hospital from May 2017 to March 2019 were selected, and they were randomly divided into control group(CCLG-ALL2008 regimen, n=31) and study group(Huaiqihuang granule combined with CCLG-ALL2008 regimen, n=31) by random number table method. The clinical symptoms situation, serum inflammatory factors, immunoglobulin levels and T lymphocyte subsets changes in the two groups were observed, and the incidence rate of adverse reactions in the two groups was recorded. Results:The average leukocyte level in the study group was higher than that in the control group, the number of infection attacks was less than that in the control group, and the use time of antibiotics was shorter than that in the control group(P<0.05). After treatment, CD3^(+), CD4^(+),CD4^(+)/CD8^(+)in the study group were higher than those in the control group, and CD8^(+)was lower than that in the control group(P<0.05).After treatment, the immunoglobulin A(Ig A) and immunoglobulin G(Ig G) in the study group were higher than those in the control group(P<0.05). There was no significant difference in immunoglobulin M(Ig M) between the control group and the study group(P>0.05). C-reactive protein(CRP), tumor necrosis factor-α(TNF-α), procalcitonin(PCT) and interleukin-6(IL-6) in the study group after treatment were lower than those in the control group(P<0.05). There was no significant difference in the total incidence rate of adverse reactions between the two groups(P>0.05). Conclusion: Huaiqihuang granule combined with CCLG-ALL2008 regimen in the treatment of children with maintenance phase of ALL can reduce children’s inflammatory reaction, improve their immune function, reduce the number of infection attacks, shorten the use time of antibiotics, which is safe and effective.